| Mai Nitta, | |
|
17700 Se 272nd St # 440, Covington, WA 98042-4951 | |
| (253) 372-7155 | |
| Not Available |
| Full Name | Mai Nitta |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 17700 Se 272nd St # 440, Covington, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578940425 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | MD60850526 (Washington) | Primary |
| Entity Name | Multicare Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497766638 PECOS PAC ID: 7719899897 Enrollment ID: O20031105000760 |
News Archive
Cortex Pharmaceuticals, Inc. announced that the rights to a published patent application entitled, "Pharmacological Modulation of Positive AMPA Receptor Modulator Effects on Neurotrophin Expression", has been licensed exclusively to Cortex from the University of California.
Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.
The discovery of the Senataxin gene, on chromosome 9q34, may provide clues to the mechanisms of related brain disorders. The study appears in the June 2004 issue of the American Journal of Human Genetics.
New research out of the University of Cincinnati is a rare examination of the social impact of armed conflict and militarization. Steve Carlton-Ford, a UC associate professor of sociology, presented the findings Aug. 11 at the 104th annual meeting of the American Sociological Association (ASA) in San Francisco.
A seven-year tracking study has prompted scientists to suggest that chronic fatigue syndrome could be the result of brain injuries inflicted during the early stages of glandular fever.
› Verified 4 days ago
| Entity Name | Peacehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720056187 PECOS PAC ID: 5890689293 Enrollment ID: O20040209000272 |
News Archive
Cortex Pharmaceuticals, Inc. announced that the rights to a published patent application entitled, "Pharmacological Modulation of Positive AMPA Receptor Modulator Effects on Neurotrophin Expression", has been licensed exclusively to Cortex from the University of California.
Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.
The discovery of the Senataxin gene, on chromosome 9q34, may provide clues to the mechanisms of related brain disorders. The study appears in the June 2004 issue of the American Journal of Human Genetics.
New research out of the University of Cincinnati is a rare examination of the social impact of armed conflict and militarization. Steve Carlton-Ford, a UC associate professor of sociology, presented the findings Aug. 11 at the 104th annual meeting of the American Sociological Association (ASA) in San Francisco.
A seven-year tracking study has prompted scientists to suggest that chronic fatigue syndrome could be the result of brain injuries inflicted during the early stages of glandular fever.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mai Nitta, P.o. Box 5299, Ms: 1313-5-pco, Tacoma, WA 98415-0299 Ph: () - | Mai Nitta, 17700 Se 272nd St # 440, Covington, WA 98042-4951 Ph: (253) 372-7155 |
News Archive
Cortex Pharmaceuticals, Inc. announced that the rights to a published patent application entitled, "Pharmacological Modulation of Positive AMPA Receptor Modulator Effects on Neurotrophin Expression", has been licensed exclusively to Cortex from the University of California.
Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.
The discovery of the Senataxin gene, on chromosome 9q34, may provide clues to the mechanisms of related brain disorders. The study appears in the June 2004 issue of the American Journal of Human Genetics.
New research out of the University of Cincinnati is a rare examination of the social impact of armed conflict and militarization. Steve Carlton-Ford, a UC associate professor of sociology, presented the findings Aug. 11 at the 104th annual meeting of the American Sociological Association (ASA) in San Francisco.
A seven-year tracking study has prompted scientists to suggest that chronic fatigue syndrome could be the result of brain injuries inflicted during the early stages of glandular fever.
› Verified 4 days ago
Dr. Callie Anne Byrd, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 27500 168th Pl Se, Covington, WA 98042 Phone: 425-690-3430 Fax: 425-690-9430 | |
Cheryl L Tan-jacobson, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 17700 Se 272nd St, Covington, WA 98042 Phone: 253-372-7156 | |
Dr. Sean Michael Verlander, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 27500 168th Pl Se, Covington, WA 98042 Phone: 253-395-2006 Fax: 253-395-1977 |